• PFOS Disrupts Sertoli Cells via the ATF2/WT1 Axis

  2026-09-26

  An integrated mouse and cell-model study links PFOS exposure to Sertoli-cell mitochondrial dysfunction and blood-testis barrier injury, identifying the ATF2/WT1 axis as a mechanistic connection. Its combination of transcriptomic, metabolomic, structural, and functional evidence—and rescue experiments—offers a framework for investigating how environmental toxicants disrupt testicular support cells.

• DAPI Nuclear Stain Solution (K2402)

  2026-09-25

  DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution provides a ready-to-use fluorescent DNA stain for nuclear visualization and endpoint assessment of membrane integrity. It is best suited to fixed or membrane-compromised samples for fluorescence microscopy or flow cytometry, not routine imaging of intact live cells or apoptosis determination on its own.

• X-Gal Beyond Blue-White Screening

  2026-09-25

  X-Gal is best understood not only as a blue-white screening reagent, but as a qualitative enzyme readout with clear interpretive boundaries. This article connects its chemistry and cloning applications to recent olfactory biology findings, showing how to choose an assay that answers the biological question.

• S1PR3 Drives Neuronal Apoptosis After ICH

  2026-09-24

  A mouse intracerebral hemorrhage model and HT22 cell experiments identify S1PR3 as a contributor to neuronal apoptosis, linking S1P stimulation with CCL2, TNF-α, PI3K/AKT signaling, and cleaved caspase-3. Pharmacological S1PR3 inhibition reduced apoptosis-associated readouts and improved neurobehavioral outcomes in the study, supporting further investigation of this receptor pathway while leaving important questions about causality and clinical translation open.

• 3-Deazaadenosine: Mechanism, Evidence & Use

  2026-09-24

  3-Deazaadenosine is a S-adenosylhomocysteine hydrolase inhibitor that can alter cellular methylation by increasing intracellular SAH and changing the SAH-to-SAM ratio. Product information also reports preclinical antiviral activity against Ebola and Marburg viruses, but these findings do not establish clinical efficacy or direct effects on m6A pathways.

• 3-Deazaadenosine: Global vs Targeted Methylation

  2026-09-23

  3-Deazaadenosine is an S-adenosylhomocysteine hydrolase inhibitor that can perturb methylation broadly, but it is not a selective probe of METTL14 or RNA m6A. This article uses a recent ulcerative colitis study to show how to distinguish metabolic methylation effects from transcript-specific regulation when designing and interpreting experiments.

• Dovitinib (TKI-258): RTK Signaling Research

  2026-09-23

  Dovitinib, also called TKI-258 and CHIR-258, is a multitargeted receptor tyrosine kinase inhibitor used to study FLT3, c-Kit, FGFR, VEGFR, and PDGFR signaling. Its reported low-nanomolar activity and downstream effects make it a useful research tool for apoptosis induction in cancer cells, but assay conditions and model context must guide interpretation.

• ATRX Deficiency Sensitizes Glioma to RTK Inhibitors

  2026-09-22

  The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data with temozolomide support ATRX-aware pharmacology and clinical-trial stratification, while remaining preliminary because the evidence is primarily cellular.

• tRF16–ALKBH5–NFKBIA Axis in Osteoarthritis

  2026-09-22

  This study identifies tRF16 as an overexpressed small RNA that worsens osteoarthritis through an ALKBH5–NFKBIA–NF-κB regulatory axis. By combining patient cartilage, an OA rat model, and IL-1β-treated chondrocytes, the work connects tRF-mediated epitranscriptomic regulation with inflammatory cartilage damage and proposes a mechanistically testable biomarker pathway.

• Romidepsin (FK228): Mechanism-to-Assay Research Guide

  2026-09-21

  Explore how Romidepsin (FK228) links selective HDAC1/2 inhibition with chromatin, apoptosis, and cell-cycle phenotypes. This guide also translates multidimensional proteomics into a practical framework for validating target engagement rather than relying on viability data alone.

• TOP1, cGAS, and PD-L1 in Cervical Cancer

  2026-09-21

  The reference study identifies a mechanistic link between HPV oncoproteins, TOP1-associated DNA damage responses, cGAS activation, and PD-L1 expression in cervical cancer. Its findings position the TOP1–cGAS–PD-L1 axis as a useful framework for studying how viral oncogenesis connects genomic stress with tumor-promoting inflammation and immune evasion.

• Dual-Pathway Nanotherapy for Gefitinib Resistance

  2026-09-20

  Deng and colleagues developed a rational combination strategy that pairs gefitinib with crizotinib to suppress PI3K–AKT signaling and compensatory ERK activation in gefitinib-resistant lung adenocarcinoma. Integrated transcriptomics, phospho-proteomics, cell models, xenografts, zebrafish metastasis assays, and a dual-drug nanoparticle platform provide a multiscale framework for addressing both resistance and metastatic progression.

• Cepharanthine in Endometriosis: Organoid and In Vivo Evidenc

  2026-09-19

  A 2026 study evaluated Cepharanthine across immortalized stromal cells, patient-derived endometriotic cells, eutopic endometrial organoids, and a murine peritoneal model. Its central finding is that this biscoclaurine alkaloid suppresses lesion growth through cell-cycle arrest, DNA damage with impaired repair, and mitochondria-associated apoptosis, while also demonstrating the value of organoids for preclinical endometriosis research.

• iRhom2 in Olfaction: OR Regulation and Adaptation

  2026-09-18

  Azzopardi and colleagues identify iRhom2 as an olfactory sensory neuron regulator linked to odorant receptor expression and activity-dependent adaptation. Their combination of knockout-mouse transcriptomics, spatial validation, and heterologous receptor activation supports an iRhom2–ADAM17 signaling model while leaving several causal and translational questions open.

• Indometacin Sodium: Assay Workflows & Optimization

  2026-09-18

  Build reproducible inflammation, proliferation, oligodendrocyte differentiation, and pathway assays with Indometacin Sodium Trihydrate. This practical guide connects concentration selection, vehicle control, mechanistic readouts, and troubleshooting to help researchers distinguish COX-dependent effects from broader cellular responses.

7997 records 1/534 page Next 12345 下5页 Last page